) --Welcome to TheStreet's live-blog coverage of the
American Society of Clinical Oncology
(ASCO) annual meeting. It's Monday, the third full day of data presentations at the largest annual gathering of cancer drug researchers in the world. More importantly, investors get the first chance to trade cancer drug stocks today following a weekend of data presentations.
On the schedule for today: An important update from
(ARIA - Get Report)
and the pivotal study of ponatinib in chronic myeloid leukemia. Also, presentation from
of phase III data from a study of regorafenib in gastrointestinal stromal tumors (GIST).
Also watch for data presentations from
(ARRY - Get Report)
Follow this live blog throughout the day for continuous updates and reports from the ASCO meeting. I'll be reporting on clinical data presentations as I see and hear them, and I'll be blogging from the hallways, exhibition hall and meeting rooms, giving you a real-time perspective on the investor-worthy buzz.
The blog will also capture tweets from a select and experienced group of analysts, doctors and journalists -- all of whom will add their perspective and insight into the ASCO meeting.
I welcome your comments and questions on this live blog, too, which I'll do my best to answer and publish as time permits.
--Written by Adam Feuerstein in Chicago.
>To contact the writer of this article, click here:
>To follow the writer on Twitter, go to
>To submit a news tip, send an email to:
and become a fan on